New developments in treatment of ovarian carcinoma: focus on trabectedin

References

• JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin20095922524919474385
   PubMed Web of Science ®Google Scholar
• GuerinSDoyonFHillCThe frequency of cancer in France in 2006, mortality trends since 1950, incidence trends since 1980 and analysis of the discrepancies between these trendsBull Cancer2009965157 French.19211360
   PubMed Web of Science ®Google Scholar
• CannistraSACancer of the ovaryN Engl J Med20043512519252915590954
   PubMed Web of Science ®Google Scholar
• HarterPHilpertFMahnerSHeitzFPfistererJdu BoisASystemic therapy in recurrent ovarian cancer: Current treatment options and new drugsExpert Rev Anticancer Ther201010818820014888
   PubMed Web of Science ®Google Scholar
• ParmarMKLedermannJAColomboNPaclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trialLancet20033612099210612826431
   PubMed Web of Science ®Google Scholar
• PfistererJPlanteMVergoteIGemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An Intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJ Clin Oncol2006244699470716966687
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineEWagnerUAvall-LundqvistEPegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapseJ Clin Oncol2010283323332920498395
   PubMed Web of Science ®Google Scholar
• PfistererJVergoteIduBAEisenhauerECombination therapy with gemcitabine and carboplatin in recurrent ovarian cancerInt J Gynecol Cancer200515Suppl 1364115839957
   PubMed Web of Science ®Google Scholar
• GordonANFleagleJTGuthrieDParkinDEGoreMELacaveAJRecurrent epithelial ovarian carcinoma: A randomized Phase III study of pegylated liposomal doxorubicin versus topotecanJ Clin Oncol2001193312332211454878
   PubMed Web of Science ®Google Scholar
• GordonANTondaMSunSRackoffWLong-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancerGynecol Oncol2004951815385103
   PubMed Web of Science ®Google Scholar
• ColomboNGoreMTreatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapyCrit Rev Oncol Hematol20076412913817566758
   PubMed Web of Science ®Google Scholar
• CannistraSAEvaluating new regimens in recurrent ovarian cancer: How much evidence is good enough?J Clin Oncol201028310110320516442
   PubMed Web of Science ®Google Scholar
• David-CordonnierMHGajateCOlmeaODNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedinChem Biol2005121201121016298299
   PubMed Web of Science ®Google Scholar
• TakebayashiYPourquierPZimonjicDBAntiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repairNat Med2001796196611479630
   PubMed Web of Science ®Google Scholar
• FriedmanDHuZKolbEAGorfajnBScottoKWEcteinascidin-743 inhibits activated but not constitutive transcriptionCancer Res2002623377338112067978
   PubMed Web of Science ®Google Scholar
• ValotiGNicolettiMIPellegrinoAEcteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenograftsClin Cancer Res19984197719839717828
   PubMed Web of Science ®Google Scholar
• HendriksHRFiebigHHGiavazziRLangdonSPJimenoJMFairclothGTHigh antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancerAnn Oncol1999101233124010586342
   PubMed Web of Science ®Google Scholar
• HerreroABMartin-CastellanosCMarcoEGagoFMorenoSCross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedinCancer Res2006668155816216912194
   PubMed Web of Science ®Google Scholar
• TakebayashiYGoldwasserFUrasakiYKohlhagenGPommierYEcteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expressionClin Cancer Res2001718519111205907
   PubMed Web of Science ®Google Scholar
• SessaCde BraudFPerottiATrabectedin for women with ovarian carcinoma after treatment with platinum and taxanes failsJ Clin Oncol2005201867187415774779
   PubMed Web of Science ®Google Scholar
• KrasnerCNMcMeekinDSChanSA Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimensBr J Cancer2007971618162418000504
   PubMed Web of Science ®Google Scholar
• Del CampoJMRoszakABidzinskiMPhase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancerAnn Oncol2009201794180219556318
   PubMed Web of Science ®Google Scholar
• McMeekinSdel CampoJMColomboNTrabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studiesASCO Meeting Abstracts20076202518 Suppl5579
   Google Scholar
• MorganJALe CesneAChawlaSRandomized Phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I). [abstract]J Clin Oncol200725Suppl 18S10060
   Google Scholar
• MutchDGOrlandoMGossTRandomized Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerJ Clin Oncol2007252811281817602086
   PubMed Web of Science ®Google Scholar
• FerrandinaGLudovisiMLorussoDPhase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancerJ Clin Oncol2008 20;2689089618281662
   PubMed Web of Science ®Google Scholar
• BlayJYvon MehrenMSamuelsBLPhase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcomaClin Cancer Res2008146656666218927308
   PubMed Web of Science ®Google Scholar
• SessaCCrestaSNoberascoCPhase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumoursEur J Cancer2009452116212219419856
   PubMed Web of Science ®Google Scholar
• von MehrenMSchilderRJChengJDA Phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignanciesAnn Oncol2008191802180918497430
   PubMed Web of Science ®Google Scholar
• MessersmithWAJimenoAEttingerDPhase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumorsCancer Chemother Pharmacol20086318118818379785
   PubMed Web of Science ®Google Scholar
• von MehrenMBuckDTemmerEElsayedYACohenRBPhase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignanciesJ Clin Oncol200624Suppl 18S2068
   Google Scholar
• ChuQMitaAForouzeshBPhase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumorsClin Cancer Res2010162656266520406837
   PubMed Web of Science ®Google Scholar
• GoreLRiveraELavalleeKPhase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignanciesJ Clin Oncol200624Suppl 18S207916648509
   PubMed Web of Science ®Google Scholar
• VidalLGarcia-MartinMTanSPhase I combination study of trabectedin and carboplatin in patients with advanced solid tumorsAnn Oncol201015Suppl 3iii1021
   Google Scholar
• MonkBJSillMWalkerJLActivity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: A Phase II study of the Gynecologic Oncology Group (GOG)J Clin Oncol201028Suppl 15504620921453
   PubMed Web of Science ®Google Scholar
• MonkBJHerzogTJKayeSBTrabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancerJ Clin Oncol2010283107311420516432
   PubMed Web of Science ®Google Scholar
• PovedaATjulandinSKongBExtending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr + PLD) versus PLD alone: Results from a PPS cohort of a phase III studyJ Clin Oncol201028Suppl 155012
   Web of Science ®Google Scholar
• PovedaAKayeSBHerzogTCorrelation of RNA expression of DNA repair genes with clinical outcomes of advanced ovarian cancer (OC) pts treated with pegylated liposomal doxorubicin (PLD) vs trabectedin (T) + PLD in the ET743-OVA-301 clinical trialEur J Cancer Suppl20097451
   Web of Science ®Google Scholar
• WeberpalsJGarbuioKO’BrienAThe DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancerInt J Cancer200912480681519035454
   PubMed Web of Science ®Google Scholar
• MatulonisUABerlinSIvyPCediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancerJ Clin Oncol2009275601560619826113
   PubMed Web of Science ®Google Scholar
• LedermannJARustinGJHackshawAA randomized Phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC)J Clin Oncol200927Suppl 15S5501
   Google Scholar
• FriedlanderMHancockKCBenignoBPazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a Phase II studyJ Clin Oncol200725Suppl 18S5561
   Google Scholar
• BryantHESchultzNThomasHDSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature200543491391715829966
   PubMed Web of Science ®Google Scholar
• FarmerHMcCabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature200543491792115829967
   PubMed Web of Science ®Google Scholar
• FongPCBossDSYapTAInhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersN Engl J Med200936112313419553641
   PubMed Web of Science ®Google Scholar
• GelmonKAHirteHWRobidouxACan we define tumors that will respond to PARP inhibitors? A Phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancerJ Clin Oncol201028Suppl 15S300220479400
   PubMed Web of Science ®Google Scholar
• FongPCYapTABossDSPoly (ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalJ Clin Oncol2010282512251920406929
   PubMed Web of Science ®Google Scholar
• KatsumataNYasudaMTakahashiFDose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trialLancet20093741331133819767092
   PubMed Web of Science ®Google Scholar